Table 2 Correlation of clinic-pathological features with MALAT1 expression in PCa TMA corhort
From: MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer
Cases | Negative | Low Positive | High Positive | pValue (X2) | |
|---|---|---|---|---|---|
(Tot 71) | |||||
Normal | 8–11.3% | 7–87.5% | 1–12.5% | 0–0% | 0.001 |
Cancer | 63–88.7% | 12–19% | 37–58.7% | 14–22.2% | |
T1-T2 | 30–47.6% | 6–20% | 23–76.7% | 1–3.3% | 0.006 |
T3-T4 | 33–52.4% | 6–18.2% | 14–42.4% | 13–39.4% | |
N0 | 51–80.9% | 11–21.6% | 34–66.7% | 6–11.7% | 0.001 |
N1 | 12–19.1% | 1–8.3% | 3–25% | 8–66.7% | |
M0 | 55–87.3 | 11–20% | 35–63.7% | 9–16.3% | 0.001 |
M1 | 8–12.7% | 1–12.5% | 2–25% | 5–62.5% | |
Stage 1-2 | 30–47.6% | 6–20% | 23–76.7% | 1–3.3% | 0.001 |
Stage 3-4 | 33–52.4% | 6–18.2% | 14–42.4% | 13–39.4% | |
WHO Grade 1-2 | 24–38.1% | 6–25% | 17–70.8% | 1–4.2% | 0.001 |
WHO Grade 3-4 | 37–58.7% | 5–13.5% | 19–51.4% | 13–35.1% |